Sorafenib monotherapy
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-SORAFENIB |
|---|
| ID | REG-SORAFENIB-MONO |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-AASLD-HCC-2023 SRC-NCCN-HCC-2025 |
Notes
SHARP trial 2008 — first systemic therapy with proven OS benefit in advanced HCC. Now 2L+ after atezo+bev / durva+treme failure, OR 1L alternative when ICI-combinations contraindicated (autoimmune disease, organ transplant). Lenvatinib (REFLECT) is non-inferior alternative with better PFS/ORR.
Used By
Indication
IND-HCC-SYSTEMIC-1L-SORAFENIB- IND-HCC-SYSTEMIC-1L-SORAFENIB